| Similar Articles |
|---|
 |
The Motley Fool
March 18, 2008
Brian Orelli |
The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?   |
BusinessWeek
February 20, 2006
Gene G. Marcial |
Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it. |
Bio-IT World
July 2005
Johan Bostrom |
Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition. |
The Motley Fool
January 28, 2005
Karl Thiel |
Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005. |
The Motley Fool
August 19, 2004
Charly Travers |
Myriad's Making Hope Possible This small biotech provides screens that can help catch cancer. Even with solid growth of product revenue, losses could continue to increase as Myriad moves more drugs into clinical development while it transitions into a drug developer. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
December 31, 2009
Brian Orelli |
Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
The Motley Fool
February 2, 2010
Brian Orelli |
Shaking Up the Biotech Industry A judge will decide if genes are patentable or not. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
Chemistry World
February 22, 2011
Amaya Camara-Campos |
Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
BusinessWeek
September 5, 2005 |
Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
The Motley Fool
September 28, 2007
Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
The Motley Fool
May 28, 2010
Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
July 23, 2011 |
Affymetrix Earnings Preview Affymetrix will unveil its latest earnings on Wednesday, July 27. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies. |
Chemistry World
January 25, 2013
Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. |
Chemistry World
June 6, 2007
Simon Hadlington |
Large-Scale Gene Scanning for Common Diseases A multi-center genome scanning project that has analyzed half a million genetic markers in thousands of healthy people and people with a range of common diseases has revealed previously unknown genetic variants of the diseases. |
The Motley Fool
May 7, 2010
Brian Orelli |
Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies. |
BusinessWeek
April 18, 2005 |
Making Those Pills Safe For Kids Few medicines get tested on children. Dr. Donald Mattison is pushing to change that. |
Chemistry World
November 12, 2013
Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold. |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
Bio-IT World
August 15, 2005
Kevin Davies |
TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification. |
The Motley Fool
November 17, 2006
Jack Uldrich |
Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
Fast Company
January 2002
George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
The Motley Fool
August 6, 2007
Brian Orelli |
Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well. |
